

as cutoff values, respectively. Qualitative assay for HBV DNA was performed by polymerase chain reaction (PCR) with primers deduced from the S region of HBV DNA.¹² HBV DNA was quantitated by the PCR (TaqMan, Roche Diagnostics KK, Tokyo, Japan) with a sensitivity of 100 copies per mL. Quantitative assays for HBV DNA were performed simultaneously for an accurate comparison of data.

Calculation for doubling time and logarithmic time of HBV DNA

To calculate the doubling time and the logarithmic time (time for reaching 10 times the amount) of HBV DNA at ramp-up after the infection, HBV DNA copy numbers were evaluated statistically by log linear regression analysis. The comparison of regression slope (the doubling time and the logarithmic time) between HBV genotypes was evaluated by growth curve analysis (Vonesh-Carter-Ohtaki method).^{13,14}

Fig. 1. Time course of HBV serum markers in chimps used as a source of inoculation of HBV genotype A and genotype C. (A) Chimp 246 was inoculated with human plasma of HBV genotype A. Inoculum II for chimp infectivity studies was harvested in the ramp-up phase of viremia before anti-HBc seroconversion at the time HBV DNA had reached a concentration of 2.6×10^6 copies per mL and the HBsAg response had increased to a signal-to-noise (S/N) ratio of 216.5 (cutoff S/N = 2.0). (B) Chimp 272 was inoculated with human plasma of HBV genotype C. Inoculum IV was harvested in the ramp-up phase of viremia before anti-HBc seroconversion at the time HBV DNA had reached a concentration of 3.0×10^6 copies per mL and HBsAg had increased to an S/N ratio of 34.0.

from chimps, plasma samples were separated. They were divided into 15 tubes in 1-mL aliquots, snap-frozen in liquid nitrogen, and kept in a deep freezer at -80°C until used for transmission experiments. For each experiment, the plasma in one tube was thawed gently by immersing it in a water bath at 37°C , and the required amounts were used.

Laboratory tests

HBsAg, anti-HBc, and antibody to HBsAg (anti-HBs) were determined by chemiluminescent immunoassay (CLIA) with commercially available kits (AxSYM, Abbott Japan, KK, Tokyo, Japan), with the index of 2.0 (signal-to-noise [S/N]), 50 percent inhibition, and 5.0 mIU per mL

RESULTS

Inocula and copy numbers of HBV genotype A or genotype C recovered from chimpanzees in the preacute phase of infection

Chimp 246 was injected intravenously with 1 mL of FFP from a blood donor in the preacute phase of HBV infection (Table 1); the donor had been screened by NAT at a JRC Blood Center. His plasma sample contained 6.9×10^4 copies per mL of HBV DNA genotype A and was positive for the presence of HBsAg but negative for the presence of anti-HBc (inoculum I). Plasma was harvested from Chimp 246, in the preacute phase of HBV infection 57 days after inoculation (inoculum II). It contained 2.6×10^6 copies per mL HBV DNA and was positive for the presence of HBsAg but still negative for the presence of anti-HBc and anti-HBs (Fig. 1A).

Likewise, Chimp 272 was injected intravenously with 5 mL of FFP from a blood donor in the preacute phase of HBV infection who had been screened by NAT at JRC (Table 1). It contained 5.3×10^5 copies per mL of HBV DNA genotype C and was positive for the presence of HBsAg but negative for the presence of anti-HBc and anti-HBs (inoculum III). Thus, Chimp 272 was inoculated with

2.7×10^6 copies of HBV genotype C. The preacute plasma sample was collected from Chimp 272 29 days after challenge (inoculum IV). It contained 3.0×10^6 copies per mL HBV DNA and was positive for the presence of HBsAg but still negative for the presence of anti-HBc and anti-HBs (Fig. 1B).

Estimates of HBV DNA copy numbers in serial 1-in-10-fold dilutions and inocula below the HBV NAT detection limit

Serial 1-in-10 dilutions of inoculum II of genotype A were prepared in preinoculation serum sample from each chimp (e.g., Chimp 272, Chimp 279, and Chimp 280, respectively). Dilutions were delivered to three tubes each in 1-mL aliquots and snap-frozen in liquid nitrogen. Concentration of HBV DNA was determined in one of the three tubes in each dilution so as to guarantee copy numbers of HBV DNA in the other two vials that were inoculated into chimps. These samples had been stored in a deep freezer at -80°C until inoculation.

Table 2 shows the measured HBV DNA concentrations in 1-in-10 dilutions of inoculum II (genotype A). The quantitative HBV DNA results starting from 2.6×10^6 copies per mL in the undiluted sample varied between 2.0×10^5 to 2.3×10^5 , 2.0×10^4 to 2.4×10^4 , 1.6×10^3 to 2.0×10^3 , and 1.7×10^2 to 2.8×10^2 copies per mL, respectively, in the 1:10, 1:10², 1:10³, and 1:10⁴ dilutions. These quantitative results are an indication of the accuracy of the dilution and assay procedure. On the premise that dilutions beyond 1:10⁴ had been performed properly, further dilutions to 1:10⁵ and 1:10⁶ would have contained 16 to 28 and 1.6 to 2.8 HBV DNA copies per mL (ranges estimated by variations of HBV DNA measurements in lower dilutions), respectively, although they were below the detection limit of the PCR method used.

Likewise, serial 1-in-10 dilutions of inoculum IV (genotype C) were prepared in the plasma sample from Chimp 269 and Chimp 285. HBV DNA in 3.0×10^6 , 3.5×10^5 to 3.8×10^5 , 3.6×10^4 to 3.9×10^4 , 3.6×10^3 to 4.6×10^3 , and 4.3×10^2 to 4.6×10^2 copies per mL were detected in the original serum samples at 1:10, 1:10², 1:10³, and 1:10⁴ dilutions thereof, respectively (Table 3). Thus, further experiments were performed on the assumption that serial dilutions of 1:10⁵ and 1:10⁶ of inoculum IV would have contained 35 to 46 and 3.5 to 4.6 HBV DNA copies per mL, respectively.

Determination of the minimum copy number required for transmission of HBV genotype A or genotype C to chimpanzees

When Chimp 272 and Chimp 279 were inoculated intravenously with 1.0 mL of inoculum II diluted 1:10⁶ (equivalent to 1.6 to 2.8 copies of HBV DNA in an in vitro assay), HBV infection did not develop in either of them during monitoring for 119 days (17 weeks) and thereafter. Chimp 279 was then rechallenged with 1.0 mL of inoculum II diluted 1:10⁵ (equivalent to 16-28 copies). He then became infected and developed HBV DNA in his serum 55 days (8 weeks) after the inoculation. Chimp 280 was also inoculated intravenously with 1.0 mL of inoculum II diluted 1:10⁵ (equivalent to 16 to 28 copies of HBV DNA). He developed HBV DNA in the circulation 76 days (11 weeks) after infection. In view of the incubation period of 55 to 76 days (8-11 weeks) for 1:10⁵ dilution of inoculum II, HBV infection would probably not have occurred in chimps who received 1:10⁶ dilution if they had been followed longer than 119 days (17 weeks).

Chimp 269 and Chimp 285 were inoculated with 1.0 mL of inoculum IV diluted 1:10⁶ (equivalent to 3.5-4.6 copies of HBV DNA in an in vitro assay). During follow-up

TABLE 2. Quantification of HBV DNA in serial 1-in-10 dilutions of the standard serum for HBV genotype A (inoculum II)*

Chimpanzee	Undiluted	Serial dilutions in preinoculation serum samples of each chimpanzee					
		1:10	1:10 ²	1:10 ³	1:10 ⁴	1:10 ⁵	1:10 ⁶
272	2.6×10^6	2.3×10^5	2.0×10^4	2.0×10^3	1.7×10^2	Not done	<100
279	2.6×10^6	2.0×10^5	2.4×10^4	2.0×10^3	2.4×10^2	<100	<100
280	2.6×10^6	2.3×10^5	2.3×10^4	1.6×10^3	2.8×10^2	<100	Not done

* Data are reported as copies per mL.

TABLE 3. Quantification of HBV DNA in serial 1-in-10 dilutions of the standard serum for HBV genotype C (inoculum IV)*

Chimpanzees	Undiluted	Serial dilutions in preinoculation serum of each chimpanzee					
		1:10	1:10 ²	1:10 ³	1:10 ⁴	1:10 ⁵	1:10 ⁶
Chimp 269	3.0×10^6	3.8×10^5	3.9×10^4	3.6×10^3	4.6×10^2	<100	<100
Chimp 285	3.0×10^6	3.5×10^5	3.6×10^4	4.6×10^3	4.3×10^2	<100	<100

* Data are reported as copies per mL.

for 112 days (16 weeks), however, no HBV infection occurred in either of them. Subsequently, they were rechallenged with 1.0 mL of inoculum IV diluted 1:10⁵ (equivalent to 35-46 copies of HBV DNA) 17 weeks after the initial inoculation. They developed HBV DNA in the circulation 35 and 50 days thereafter, respectively, indicating that both of them were infected. Therefore, the 50 percent chimp infectious dose (CID₅₀) for both genotype A and genotype C lies between the lowest infectious dose of approximately 30 copies and the subinfectious dose of approximately 3 copies or at approximately 10 HBV DNA copies.

HBV infection resolved in all six chimps and they never became carriers. Within a few weeks after the peak

HBV DNA titer was reached, serum levels of transaminase increased slightly, within 3 times the upper limit of normal.

Replication velocity of HBV DNA in the preacute phase of infection

Doubling time and logarithmic time of HBV genotype A
 Figure 2A illustrates the appearance of HBV genotype A in the circulation, when HBV DNA reached more than 10² copies per mL, as well as its early dynamics in Chimp 246, Chimp 279, and Chimp 280 during the preacute phase of exponential replication. HBV DNA emerged in the circulation earlier in Chimp 246 than the other two chimps, but




Fig. 2. Log-linear increase of HBV DNA in the circulation of chimpanzees during the early exponential replication phase. (A) Dynamics in the early ramp-up phase of viral DNA for three chimps inoculated with HBV genotype A: one chimp (Chimp 246) received 1 mL of human plasma containing 6.9×10^4 copies and the other two chimps (Chimps 279 and 280) received 1 mL of a 100,000 dilution of chimp plasma taken in the HBsAg ramp-up phase just before appearance of anti-HBc, which dilution contains a measured amount of 16 to 28 copies. (B) Graph summarizes the viral load dynamics for three chimpanzees inoculated with HBV genotype C: one chimp (Chimp 272) received 5 mL of human plasma with 2.7×10^6 copies of HBV DNA and the two other chimps (Chimps 269 and 285) received a measured amount of 35 to 46 copies (1:100,000 dilution) of preacute-phase chimpanzee plasma. Shaded areas are below the detection limit of NAT (<100 copies/mL). Only the phase of exponential replication is shown, and HBV DNA decreased after it reached peak values of 5.7×10^5 to 2.8×10^9 copies per mL in three chimps inoculated with HBV genotype A and 1.1×10^7 to 4.6×10^9 copies per mL in three chimps inoculated with HBV genotype C.

this animal had received more than a 1000-fold larger amount of copies of HBV than the other two chimps. Despite the 1000-fold higher infectious dose, the log-linear increase of HBV DNA in Chimp 246 was the same as in Chimp 279, who had received the minimum infectious dose. In Chimp 246, HBV DNA replicated exponentially from 21 to 97 days (3-13 weeks) until it peaked and then declined. Even though the same minimum infectious dose of HBV was inoculated, Chimp 279 developed detectable HBV DNA about 21 days (3 weeks) earlier than Chimp 280, in whom HBV replicated slightly slower. Despite differences in HBV doses and individual variation, the replication velocity was constant for HBV genotype A in the preacute phase of infection, before innate immune responses of the host developed, while the virus replicated at an exponential rate. The doubling time and the logarithmic time, in the early exponential viral replication phase, were calculated to be 2.7 to 4.4 and 9.0 to 14.7 days, respectively (see Table 4).

Doubling time and logarithmic time of HBV genotype C
The replication velocity in the preacute phase of infection in chimpanzees inoculated with genotype C inocula was faster than in the chimps infected with HBV of genotype A (Fig. 2B). Again, slight variation in log-linear increase of HBV DNA was found, and HBV DNA appeared in serum earlier in Chimp 272 who was inoculated with a 100,000-fold higher infectious dose than was administered to Chimps 269 and 285. As seen in the chimps inoculated with HBV genotype A, HBV genotype C increased in a log-linear fashion in the absence of host immune responses. Doubling times of HBV DNA in the circulation of Chimp 272, Chimp 269, and Chimp 285 were calculated to be 1.7 to 2.5 days and logarithmic times were 5.6 to 8.3 days as determined with the regression formula shown in Table 4.

When comparing the replication velocity of HBV DNA between the two genotypes estimated by a growth curve, the difference was significant ($p < 0.01$, Table 5). That is, the doubling time of replications of HBV DNA with genotype A was estimated to be 3.44 days (95% confidence interval [CI], 2.64-4.89 days) and the logarithmic time was estimated to be 11.42 days (95% CI, 8.80-16.26 days). By contrast, those with HBV genotype C were estimated to be 1.90 days (95% CI, 1.63-2.27 days) and 6.30 days (95% CI, 5.41-7.54 days), respectively.

TABLE 4. Estimated doubling times and logarithmic times for HBV genotypes A and C with log-linear and growth-curve analysis

Genotype	Doubling time (days)	Logarithmic time (days)	y = a × exp(b × x)		
			a	b	R ²
Genotype A					
Chimp 246	2.71	9.01	0.8491	0.2556	0.997
Chimp 279	3.05	10.14	0.0015	0.2271	0.998
Chimp 280	4.43	14.73	0.0022	0.1563	0.999
Genotype C					
Chimp 272	1.68	5.58	0.2074	0.413	0.998
Chimp 269	1.79	5.96	0.0002	0.3863	0.999
Chimp 285	2.5	8.31	0.0009	0.2771	0.997

TABLE 5. Comparing the replication velocity of HBV DNA between the two genotypes estimated by a growth curve

Genotype	Doubling time (95% CI), days	Logarithmic time (95% CI), days	y = a × exp(b × x)		
			a*	b (95% CI)	p Value
A	3.44 (2.64-4.89)	11.42 (8.80-16.26)	2.299	0.2017 (0.14-0.26)	<0.01
C	1.9 (1.63-2.27)	6.3 (5.41-7.54)	2.299	0.3654 (0.31-0.43)	

* To evaluate the difference of "b" (that is, slope) between the two genotypes, the growth curve model is assuming that "a" is identical.¹³

TABLE 6. Window periods before HBV DNA and HBsAg developed in the circulation of chimpanzees inoculated with the minimum infectious dose of genotype A or genotype C

HBV inoculated	Chimp infected	Markers of HBV infection	
		HBV DNA (days)	HBsAg (days)
Genotype A	279	55	69
	280	76	97
Genotype C	269	35	50
	285	50	64

Window periods of HBV DNA and HBsAg in chimpanzees inoculated with the minimum infectious dose of HBV

After inoculation, the time before HBV DNA becomes detectable in the circulation by the single-sample NAT (with a sensitivity of 10² copies/mL) and the time before HBsAg was detected by CLIA after inoculation are listed in Table 6. The HBV DNA (<100 copies/mL) NAT window was 55 and 76 days, respectively, in Chimp 279 and Chimp 280 inoculated with the lowest infectious dose of HBV genotype A (approx. 30 copies). These NAT window periods were longer than the 35 and 50 days, respectively, found in Chimp 269 and Chimp 285 inoculated with the lowest infectious amounts of HBV genotype C (approx. 30 copies). Likewise, the HBsAg window was longer in Chimp 279 and Chimp 280 infected with genotype A than in Chimp 269 and Chimp 285 infected with genotype C (69 and 97 days, respectively, vs. 50 and 64 days, respectively).

DISCUSSION

Animal models sensitive to human hepatitis viruses offer robust advantages in obtaining basic data of viral infectivity.¹⁰ By experimental infection of chimps with HCV, we have been able to determine the minimum infectious dose of HCV required for establishing infection.^{15,16} The doubling time of HCV was determined to be 6.3 to 8.6 hours in two chimps inoculated with the minimum infectious dose of approximately 10 copies of HCV RNA. During the first 5 days after inoculation, HCV RNA did not increase above the NAT detection limit of 10^2 copies per mL in the circulation.¹⁶ It would not be possible to detect HCV infection during the initial few days after exposure, even if 1-mL samples were used for individual NAT.

In this study, we have determined the minimum infectious dose for two standardized inocula containing defined copy numbers of HBV DNA. They were plasma passages of HBV in chimps harvested during the preacute phase of infection and had been processed with the utmost care for maintaining infectious activity. The minimum infectious dose of HBV or the dose where 50 percent of the chimps would be infected lies between 1-in-1 million and 1-in-100,000 dilution of the original inocula and is estimated to be of the order of 10 copies, as was the case for HCV.¹⁵ On the basis of HBV DNA concentrations measured in serial dilutions of inocula (Tables 2 and 3), the minimum infectious dose can be determined to be 16 to 28 copies for HBV genotype A and 35 to 46 copies for HBV genotype C.

There are two definitions of the minimum infectious dose of HBV. Theoretically, it is a single copy of HBV. Not all HBV virions entering the circulation of recipients, however, will succeed in reaching hepatocytes, because some of them are phagocytized by circulating macrophages and Kupffer cells in the sinusoids of the liver. In a mathematical window-phase risk model, Weusten and colleagues⁹ have proposed a minimum infectious dose approximately 10 copies of HBV, on the basis of the CID_{50} .¹⁷⁻¹⁹ Recently the inocula derived from chronic HBV carriers used in older chimpanzee studies^{17,18} were requantified by Hsia and coworkers²⁰ with real-time TaqMan PCR. The estimated HBV copy number per CID_{50} (geq) was 169 for genotype A *adu*, 78 for genotype D *ayu*, and 3 for genotype C *adr*, calculated by mathematical division, respectively. These viral load data, performed on cryopreserved aliquots from an inocula derived from a chronic HBV carrier (i.e., HBsAg- and anti-HBc-positive), were derived retrospectively several decades after the chimp titration studies. These results are different from the results obtained in our study, where the inocula was derived from the early ramp-up phase of viremia (HBsAg is positive but anti-HBc is negative) and the chimp titration and viral load analyses were performed prospectively.

Hence, the minimum infectious dose defined as a single copy, proposed on a theoretical basis, would deserve revisiting in practical HBV infections. The window period of HBV infection changes with the size of the inoculum. The more copies of HBV inoculated therefore the shorter the incubation period in experimental transmission studies in chimps.¹¹ An inverse correlation is reported, also, between time before HBsAg appears in serum and the HBV dose in human beings.²¹ In accordance with these reports, we also found that the NAT window was shorter in chimps receiving larger sizes of inocula both for genotypes A and C (Fig. 2). The NAT (<100 copies/mL) window period was approximately 1 week with an inoculum of 2.7×10^6 copies of genotype C, approximately 3 weeks with 6.9×10^4 copies of genotype A, 5 to 7 weeks when inoculating 35 to 46 copies of genotype C, and 8 to 11 weeks when inoculating 16 to 28 copies of HBV genotype A, while no infection was observed during 16 to 17 weeks of observation with an inocula of approximately 3 copies of genotype A or B. Theoretically, HBV infection might have become detectable after 17 weeks, but this is unlikely when extrapolating the data above. Inoculation with HBV in large amounts, as happens with transfusion with HBsAg-positive blood units, has been largely excluded since introduction of HBsAg testing in 1972. Barker and Murray²¹ have shown that inoculation of lower infectious doses of HBV in the range of 10^4 to 10^7 diluted icteric plasma no longer caused clinical hepatitis in healthy individuals, while infection still occurred with up to a 10^7 diluted inoculum, as detected by an HBsAg complement fixation test. Our study showed that HBV DNA levels increase 6.5×10^3 to 2.2×10^5 copies per mL at the time of the first HBsAg-reactive sample in six chimpanzees in whom blood samples were taken at intervals of 2 to 7 days. These amounts are enough to cause clinical hepatitis B.²¹ Indeed, Satake and coworkers³ found that transmission of 5,000 to 50,000 copies of HBV by blood components with a low viral load in the pre-MP-NAT window phase could cause clinical hepatitis B. Transfusion-transmitted HBV after introduction of individual-donation or small-pool NAT (<10) is still possible, but would involve relatively low infectious doses of HBV of approximately 10 to 100 CID_{50} .

In the chimps inoculated with approximately 30 copies of HBV, the NAT window was determined by individual-donation NAT having a sensitivity of 10^2 copies per mL, while the HBsAg window was established by CLIA with the highest sensitivity presently available.^{5,12} The NAT window was 55 to 76 days and HBsAg window was 69 to 97 days, respectively, in Chimp 279 and Chimp 280 who had been inoculated with approximately 30 copies of HBV genotype A. In contrast, the NAT window was 35 to 50 days and the HBsAg window was 50 to 64 days, respectively, for Chimp 269 and Chimp 285 inoculated with approximately 30 copies of HBV genotype C. Thus, neither

the NAT nor the HBsAg window phases overlapped between minimum-dose infections of HBV genotypes A and C; they were longer for genotype A than genotype C. It may be that the NAT window is longer for genotype A, prevalent in Western countries, than genotype C common in Japan. It cannot be excluded, however, that the results observed in our inoculation studies with a limited number of chimpanzees were influenced by the host rather than the genotype of the virus. The duration of the NAT and HBsAg windows are influenced at least by three factors: 1) the infectious dose, 2) individual variation among recipients, and 3) distinct HBV genotypes.

We found the replication velocity of HBV in the preacute phase of infection remarkably different between genotypes A and C. From three chimps infected with HBV genotype A, the doubling time was estimated to be 3.44 days (95% CI, 2.64-4.89 days) and the logarithmic time 11.42 days (95% CI, 8.80-16.26 days). From three chimps infected with HBV genotype C, the doubling time was estimated to be 1.90 days (95% CI, 1.63-2.27 days), and the logarithmic time 6.30 days (95% CI, 5.41-7.54 days). Also in chimeric mice with the liver replaced by human hepatocytes, genotype A was found to replicate much slower than genotype C in the initial weeks of HBV infection.²²

The replication velocity of HBV in the circulation, indicated by the viral doubling time, is an important factor when calculating the window-period reduction provided by NAT screening systems. Biswas and colleagues⁵ calculated a doubling time of 2.56 days (95% CI, 2.24-2.97 days) based on a seroconversion panel of 23 HBV infections. Yoshikawa et al.⁴ followed 93 donors in preacute phase HBV infections who had been identified by the routine NAT screening program on 50-MPs at JRC Blood Centers. They estimated a median doubling time of HBV at 2.6 days (range: 1.3-15.2).

Kleinman and Busch⁷ have assessed the HBsAg window period based on the HBV doubling time of 2.56 days documented by Biswas and colleagues.⁵ They estimated an HBsAg window at 38.3 days (95% CI, 33.0-43.7 days) by the CLIA HBsAg seroconversion point at a concentration of 1650 copies per mL, while Minegishi and coworkers¹² determined the HBsAg seroconversion point at 2100 copies per mL. We found the HBsAg seroconversion with AxSYM occurred when the HBV DNA concentration reached a level of 6.5×10^3 to 2.2×10^5 in six chimpanzees. The differences in HBV levels at HBsAg seroconversion in CLIA may be related to the genotype, but also could reflect differences in the calibration of HBV quantitative assays in genome copies.

It is not known if the chimpanzee model is as susceptible for HBV infection as human beings. As a result, the minimum dose of HBV for transmitting infection to man is, in fact, not precisely known. Nevertheless, a minimum human infectious dose of approximately 10 HBV DNA copies, as indicated by our chimpanzee infectivity experi-

ments, seems a reasonable assumption for modeling the HBV transmission risk in the pre-HBV-NAT window period.

ACKNOWLEDGMENTS

We thank members of two Japanese Red Cross Blood Centers for providing us with plasma samples in the HBsAg window and staff of Primate Park, Sanwa Kagaku Kenkyusho, in Kumamoto for caring for the chimps used in this study. We thank Dr Nico Lelie for his assistance in preparing the manuscript and thank Prof. Megu Ohtaki for his advice in analyzing the statistical difference of slopes in two genotypes. This work has been conducted as a part of viral hepatitis research by the taskforce under the auspices of the Ministry of Health, Labor and Welfare of Japan.

REFERENCES

1. Japanese Red Cross Non-A, Non-B Hepatitis Research Group. Effect of screening for hepatitis C virus antibody and hepatitis B virus core antibody on incidence of post-transfusion hepatitis. *Lancet* 1991;338:1040-1.
2. Kojima M, Shimizu M, Tsuchimochi T, Koyasu M, Tanaka S, Iizuka H, Tanaka T, Okamoto H, Tsuda F, Miyakawa Y, Mayumi M. Posttransfusion fulminant hepatitis B associated with precore-defective HBV mutants. *Vox Sang* 1991; 60:34-9.
3. Satake M, Taira R, Yugi H, Hino S, Kanemitsu K, Ikeda H, Tadokoro K. Infectivity of blood components with low HBV-DNA levels identified in a look back program. *Transfusion* 2007;47:1197-205.
4. Yoshikawa A, Gotanda Y, Itabashi M, Minegishi K, Kanemitsu K, Nishioka K. HBV NAT positive [corrected] blood donors in the early and late stages of HBV infection: analyses of the window period and kinetics of HBV DNA. *Vox Sang* 2005;88:77-86.
5. Biswas R, Tabor E, Hsia CC, Wright DJ, Laycock ME, Fiebig EW, Peddada L, Smith R, Schreiber GB, Epstein JS, Nemo GJ, Busch MP. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. *Transfusion* 2003;43:788-98.
6. Busch MP, Glynn SA, Stramer SL, Strong DM, Caglioti S, Wright DJ, Pappalardo B, Kleinman SH; NHLBI-REDS NAT Study Group. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. *Transfusion* 2005;45: 254-64.
7. Kleinman SH, Busch MP. Assessing the impact of HBV NAT on window period reduction and residual risk. *J Clin Virol* 2006;36 Suppl 1:S23-9.
8. Yugi H, Mizui M, Tanaka J, Yoshizawa H. Hepatitis B virus (HBV) screening strategy to ensure the safety of blood for transfusion through a combination of immunological testing and nucleic acid amplification testing—Japanese experience. *J Clin Virol* 2006;36 Suppl 1:S56-64.

9. Weusten JJ, van Drimmelen HA, Lelie PN. Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window-phase donations not detected by NAT. *Transfusion* 2002;42:537-48.
10. Prince AM, Brotman B. Perspectives on hepatitis B studies with chimpanzees. *ILAR J* 2001;42:85-8.
11. Shikata T, Karasawa T, Abe K, Uzawa T, Suzuki H, Oda T, Imai M, Mayumi M, Moritsugu Y. Hepatitis B e antigen and infectivity of hepatitis B virus. *J Infect Dis* 1977;136: 571-6.
12. Minegishi K, Yoshikawa A, Kishimoto S, Yugi H, Yokoya N, Sakurada M, Kiyokawa H, Nishioka K. Superiority of minipool nucleic acid amplification technology for hepatitis B virus over chemiluminescence immunoassay for hepatitis B surface antigen screening. *Vox Sang* 2003;84: 287-91.
13. Ohtaki M, Satoh K, Kanda T, Fujikoshi Y. Local ridge estimate using random coefficient curve models for analyzing repeated measurements. *J Jpn Stat Soc* 2007;36:177-84.
14. Vonesh EF, Carter RL. Efficient inference for random-coefficient growth curve models with unbalanced data. *Biometrics* 1987;80:642-50.
15. Katayama K, Kumagai J, Komiya Y, Mizui M, Yugi H, Kishimoto S, Yamanaka R, Tamatsukuri S, Tomoguri T, Miyakawa Y, Tanaka J, Yoshizawa H. Titration of hepatitis C virus in chimpanzees for determining the copy number required for transmission. *Intervirology* 2004;47:57-64.
16. Tanaka J, Katayama K, Kumagai J, Komiya Y, Yugi H, Kishimoto S, Mizui M, Tomoguri T, Miyakawa Y, Yoshizawa H. Early dynamics of hepatitis C virus in the circulation of chimpanzees with experimental infection. *Intervirology* 2005;48:120-3.
17. Berninger M, Hammer M, Hoyer B, Gerin JL. An assay for the detection of the DNA genome of hepatitis B virus in serum. *J Med Virol* 1982;9:57-68.
18. Ulrich PP, Bhat RA, Seto B, Mack D, Sninski J, Vyas GN. Enzymatic amplification of hepatitis B virus DNA in serum compared with infectivity testing in chimpanzees. *J Infect Dis* 1989;160:37-43.
19. Prince AM, Stephan W, Brotman B. Beta-propiolactone/ultraviolet irradiation: a review of its effectiveness for inactivation of viruses in blood derivatives. *Rev Infect Dis* 1983; 5:92-107.
20. Hsia CC, Purcell RH, Farshid M, Lachenbruch PA, Yu MY. Quantification of hepatitis B virus genomes and infectivity in human serum samples. *Transfusion* 2006;46:1829-35.
21. Barker LF, Murray R. Relationship of virus dose to incubation time of clinical hepatitis and time of appearance of hepatitis-associated antigen. *Am J Med Sci* 1972;263:27-33.
22. Sugiyama M, Tanaka Y, Kato T, Orito E, Ito K, Acharya SK, Gish RG, Kramvis A, Shimada T, Izumi N, Kaito M, Miyakawa Y, Mizokami M. Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. *Hepatology* 2006;44:915-24. ■

国内で販売されている抗 HBs 抗体定量用 体外診断用医薬品の評価：国内標準品を用 いた検討*

水落利明¹⁾/小高千加子¹⁾/山口一成¹⁾

(SUMMARY) 国内で販売されている8種類の抗 HBs 抗体測定キットを用いて、抗 HBs ヒト免疫グロブリン(以下、抗 HBs 抗体)国内標準品の希釈系列検体を測定した。6種類のキットにおいてはほぼ期待される測定値を示した。しかしながら、期待値に比較して約0.5倍と1.5倍の測定値を示すキットが各1種類あった。このような乖離の原因を調査しその修正が行われた結果、1種類のキットは新規申請に向けて開発中であり、もう一種類のキットでは一部変更の手続きが行われている。これにより今後はHBV感染防御の基準と考えられる抗体価の“10 mIU/ml”という数値について、いずれのキットを用いてもほぼ均一な定量が可能になることが期待される。

(KEYWORDS) HBV, 抗 HBs 抗体測定キット, 抗 HBs 抗体国内標準品

■ 緒言

HBV (hepatitis B virus) 感染者数は全国民の約2%にも及ぶと推定されており、B型肝炎は「国民病」とも言われている。HBV感染防御については、安全で副作用の少ないワクチンが既に開発され、わが国ではハイリスクグループおよびHBV感染者から出産した児に投与され効果をあげている。HBV感染防御に有効な抗HBs抗体価については、WHO(世界保健機関)やCDC(米国

疾病予防管理センター)では10 mIU/mlという数値を提唱している¹⁻³⁾。日本国内においても同様な基準を採用するかについては議論の余地があるが、それ以前の問題として、現在国内で使用されている様々な抗HBs抗体測定キット(定量キット)が、お互いに乖離がない測定値を提供できるかについての検証がなされていない。本研究では、抗HBs抗体国内標準品(WHO国際標準品を用いて値付けしたもの)の希釈系列検体を、国内で販売されている8種類の測定キットを用いて測定し、その値を比較検討した。

■ 材料および方法

1. 抗HBs抗体国内標準品

原料はグラクソスミスクライン社製 ENGER-IX-B®(HBs抗原のサブタイプは adw と考えられる)の接種により抗体価を高めた国外血由来の血漿である。内容物は白色粉末凍結乾燥品で、1バイアル(含湿度0.5%)を1.0 ml 注射用水で溶解したとき320 IU/mlとなる。また pH=6.94, 浸透圧=1.65, 蛋白質含量=29.2 mg/ml, 免疫グロブリンG含量=99.6%であり、HBsAg, HAV-RNA, HBV-DNA, HCV-RNA, HIV-1-RNAはすべて陰性である。なお本標準品の力価は国際標準品(WHO 1st, 1977)を基にして値付けされ、2001年4月より国立感染症研究所から供与され

* Evaluation of anti-HBs antibody assay kits commercially available in Japan by utilizing the national standard

1) MIZUOCHI Toshiaki, ODAKA Chikako, YAMAGUCHI Kazunari : Department of Research on Blood and Biological Products, National Institute of Infectious Diseases
国立感染症研究所 血液・安全性研究部
(〒208-0011 東京都武蔵村山市学園4-7-1)

表 使用した抗 HBs 抗体測定キットの名称, 測定方法, および抗体検出に用いた HBs 抗原のサブタイプ

Kit No.	メーカー名	製品名	原理/方法
1	アボット・ジャパン	アキシム オーサブ・ダイナバック	EIA
2	アボット・ジャパン	アーキテクト・オーサブ	CLIA
3	アボット・ジャパン	IMx オーサブ・ダイナバック	EIA
4	オーソ・クリニカル・ダイアグノスティックス	ビトロス HBs 抗体	CLEIA
5	東ソー	E テスト「TOSOH」II (HBsAb)	EIA
6	デイドベアリング	エンザイグノスト Anti-HBs II	EIA
7	富士レビオ	ルミパルス II HBsAb	CLEIA
8	和光純薬	スフィアライト HBs 抗体	CLEIA

CLIA : chemiluminescent immunoassay (蛍光免疫法).

EIA : enzyme immunoassay (酵素免疫法).

CLEIA : chemiluminescent enzyme immunoassay (蛍光酵素免疫法).

ている。

2. 希釈系列作成手順

- (1) 抗 HBs 抗体国内標準品 (320 IU/vial) 1 バイアルを 1 ml の精製水で溶解した。
- (2) 標準品溶液 0.1 ml に検体希釈液 9.9 ml を加え均一な溶液にした (3,200 mIU/ml)。
- (3) 3,200 mIU/ml の溶液を 5 倍希釈 (溶液 1 ml + 検体希釈液 4 ml) して 640 mIU/ml の抗体液 (5 ml) を作成した。
- (4) 以下, 順次 2 倍希釈系列を作成した。
(2.5 ml + 2.5 ml) 系列 : 0, 10, 20, 40, 80, 160, 320, 640 (mIU/ml)。

3. 抗 HBs 抗体測定キット

抗 HBs 抗体測定に使用したキットは, 表に示した 8 種類である。測定は各検体につき 3 重測定で行った。

■ 結果

図 1 は各キットでの抗 HBs 抗体国内標準品希釈系列検体の測定結果である。いずれのキットも測定範囲内 (0~640 mIU/ml) で期待値と測定値の関係において非常に良好な直線性が得られた ($r^2 = 0.98 \sim 1.00$)。しかし, キット #7 と #8 では直線の傾きがそれぞれ 1.7, および 0.56 と理想である 1.0 からの明らかな乖離がみられた。そこで, 対表示値を算定し, それらの結果を図 2 にまとめた。ここでの対表示値とは, 各検体の抗体濃度 (期待値) と測定値の比を, 各濃度ごとに計算しそ

れらを平均した値のことである。したがって理想的な対表示値は 100 となる。

図 2 に示したように, #1~#6 のキットではおおよそ 120 前後の対表示値を示しているが, 図 1 の結果から予想されたように, キット #7, #8 の対表示値はそれぞれ 169.2 および 50.1 であり, 100 からの乖離が大きかった。なお WHO や CDC が提唱している, HBV 感染防御に有効な免疫獲得の基準と考えられる 10 mIU/ml の低濃度検体を用いた測定値を比較したところ, 図 2 に示した「対表示値」と良く相関していることが確認された。このような測定値乖離の原因について, それぞれのメーカーと協議した結果, 以下の結論に達した。#7 においてはキットを製造する際の検討に, WHO 国際標準品の抗 HBs 抗体を基準にしていなかったことが原因であると結論された。そこで現在新たなキットが開発され, それを用いた測定では対表示値が 117.2 となった (未発表データ)。また #8 においては, 乖離の原因は不明であるが, WHO 国際標準品を用いて見直しを行い, 再測定の結果, 対表示値が 88.4 となった (未発表データ, なおこのキットは現在一部変更申請中である)。

■ 考察

現在国内における抗 HBs 抗体価の表示には, 凝集法による「管数」表示と, EIA (enzyme immunoassay), CLIA (chemiluminescent immuno-




図1 各キットを用いた抗HBs抗体希釈系列検体の測定結果

表に示した8種類のキットを用いて抗HBs抗体国内標準品の希釈系列検体(0~640 mIU/ml)を測定した結果を表す。なお、図におけるキットの番号は、表におけるキットの番号に対応する。




図2 各キットの対表示値

対表示値 (%)とは、各検体の抗体濃度(期待値)と測定値の比を各濃度ごとに計算し、それらを平均した値のことである。

assay), CLEIA 法による「mIU/ml」表示の両者が混在して用いられている。しかし今後は国際的調和の観点からも、WHO の国際標準品を基にした「mIU/ml」に統一されるべきである。また“緒言”でも述べたように、HBV 感染防御に有効な抗 HBs 抗体価の基準について、WHO や CDC が提唱する 10 mIU/ml という基準についてわが国でも詳細に検討するべき時期がきている。以上の観点から、現在国内で承認を受け販売/使用されている抗 HBs 抗体測定キットにおいて、同一検体系列を測定しその結果を比較した場合、使用するキットによる測定結果に乖離がないことが今後の基準作成の前提条件となるだろうと考える。

本研究の結果から、現在国内で使用されている 8 種類のキットのなかで、6 種類のキットにおいてはほぼ同様の測定値を示したが、2 種類のキットではそれぞれ約 1.5 倍、約 0.5 倍の測定値を示した(図 2)。この結果は Ogata によってすでに報告されているアーキテクト(#2)とルミパルス(#7)における測定値の乖離と良く一致する^{4,5)}。そこでこれらのキットについて製造メーカーと検討した結果、その原因が判明し、それに従いキットが改善されることとなった。そして、それぞれのキットにおいて現在申請に向けて開発中、および一部変更申請が行われている。したがって、こ

れらの申請が認められた段階では、8 種類すべてのキットで同一検体に対してほぼ同一の測定値を示すことになるだろう。

今後は HB ワクチン投与の有効性(感染防御能の獲得)を検証するためにも、抗 HBs 抗体価の正確な測定が重要である。そのためには測定キット間での測定結果に乖離がないことが必須であり、今回の報告でそれが実現されつつあることが示された。

謝辞

本研究における抗 HBs 抗体価の測定にあたり、各キットの製造/販売会社の方々に多大な御協力をいただきましたことを深謝いたします。また本研究の遂行にあたり、数多くの御助言をいただきました燕労災病院の小方則夫博士に深く御礼申し上げます。

文 献

- 1) Meeting on hepatitis B control through immunization. RS/2002/GE/05, Japan, 2002
- 2) A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States. Part 1 : Immunization of Infants, Children, and Adolescents. MMWR 54(RR16) : 1-23, 2005
- 3) A Comprehensive Immunization Strategy to Elimi-

nate Transmission of Hepatitis B Virus Infection in the United States. Part II : Immunization of Adults. MMWR 55(RR16) : 1-25, 2006

- 4) Ogata N : Requirement of standardizing anti-HBs assay methods in Japan for HBV infection-preventing strategy-discrepancy of anti-HBs measurements among three different kits widely used in Japan. Rinsho Byori 54 : 960-965, 2006

- 5) Ogata N : Measurements in international units of antibody to hepatitis B surface antigen (anti-HBs) after immunization with a yeast-derived, subtype adr hepatitis B vaccine are considerably different between chemiluminescent immunoassay (CLIA) and chemiluminescent enzyme immunoassay (CLEIA). Rinsho Byori 54 : 340-343, 2006

許諾済複写物シールについてのお知らせ

日本著作出版権管理システム

JCLSが許諾した複写物には、許諾済複写物シールが貼付されています。

日本著作出版権管理システム(JCLS)が正規に許諾した複写物のうち、

- ①スポット契約(個人や団体の利用者が複写利用のつど事前に申告してJCLSがこれを許可する複写利用契約)の複写物
- ②利用者による第三者への頒布を目的とした複写物
- ③JCLSと利用契約を締結している複写事業者(ドキュメントサプライヤー=DS)が提供する複写物

については、当該複写物が著作権法に基づいた正規の許諾複写物であることを証明するため、下記見本の「許諾済複写物シール」を2006年1月1日より複写物に貼付いたします。

なお、社内利用を目的とした包括契約(自社の保有資料を自社で複写し、自社内で使用)分の複写物にはシール貼付の必要はありません。

許諾済複写物シールについてのお問い合わせは、
(株)日本著作出版権管理システム(JCLS)までお願い申し上げます。
電話 03-3817-5670、Fax 03-3815-8199、E-mail : info@jcls.co.jp



シール見本(実物は直径17mm)